anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent large randomized multicenter trials have investigated the effects of lowering blood glucose levels towards normal in both inpatient and ambulatory care/community settings. All studies have reported increasing prevalence and incidence of hypoglycemia as glucose levels approach normal. In fact, the occurrence of hypoglycemia was so problematic that some hospital based studies were halted and the target recommendations for glucose levels in critically unwell patients have been increased. Similarly three recent large glucose control and complications trials in type 2 diabetes mellitus (DM) have reported significantly high rates of hypoglycemia in intensively treated type 2 DM individuals. In two of these studies (VADT, ADVANCE) there was a highly significant association between severe hypoglycemia (glucose low enough to cause neurologic impairment) and serious cardiac events and increased death. Furthermore, in two studies performed in the USA (VADT, ACCORD), severe hypoglycemia occurring in the standard/conventionally treated group produced even more serious adverse cardiac effects as compared to the intensively treated group. The in-vivo mechanism(s) responsible for the above findings could not be identified from the above studies. Surprisingly there is very limited data available regarding the effects of hypoglycemia on in-vivo vascular biology. Previously, in vitro work has determined that epinephrine, norepinephrine, growth hormone, glucagon, and corticosteroids (all counterregulatory hormones) can have vascular biologic effects (platelet aggregation, fibrinolytic balance, increases in pro-inflammatory markers and changes in endothelial function). Three recent studies from my own and other laboratories performed in healthy volunteers and type 1 DM have demonstrated that hypoglycemia can produce a spectrum of pro-inflammatory and pro-atherothrombotic changes. Novel preliminary data from my lab has also demonstrated that hypoglycemia can impair endothelial function, reduce fibrinolytic balance (increase plasminogen activator inhibitor-1) and produce pro-atherothrombotic (increase platelet aggregation, thrombin anti-thrombin complexes, vascular adhesion molecules) changes in type 2 DM. Additionally, preliminary data presented below will demonstrate that a 90 minute episode of hypoglycemia (50 mg/dl) produces similar pro-atherothrombotic changes as compared to 4 hours of hyperglycemia (200 mg/dl). However, as investigators are just beginning to realize the effects of hypoglycemia on vascular biology, there remain many unanswered questions. For example, in the vulnerable type 2 DM population what is the dose response of different levels of hypoglycemia with attendant ANS activation on endothelial function and atherothrombotic balance? How does level of glycemic control affect ANS and vascular biologic responses to hypoglycemia in type 2 DM? Proposed studies in this protocol will provide novel information answering the clinically important question regarding the effects of mild to moderate hypoglycemia on vascular biologic mechanisms in a healthy population.
PURPOSE:To obtain a thrombin powder preparation useful for promoting hemostasia, not reducing thrombin titer, having storage stability, being readily partially injected in powder by using lactose as an excipient. CONSTITUTION:Lactose is used as an excipient. For example, thrombin obtained by fractionation of plasma protein or by genetic engineering, namely thrombin prepared by treating prothrombin purified from human plasma with thromboplastin in the presence of Ca<2+> is used as the thrombin. Thrombin having about 100-1,000 units/mg protein specific activity is preferably used. The amount of lactose added to thrombin powder is about 50-100mg based on 500-10,000 unit thrombin, namely thrombin activity based on 1mg of the preparation can be adjusted to about 10 units. The powder preparation can be used in stick packaging and considered to be effective for clinical use.
Paranoia-Focused Cognitive Behavioral Therapy (PFCBT) is a manualized intervention that combines group and individual modalities to reduce paranoia-biased information-processing and social avoidance, and to increase insight and reality testing capacity.

This is a randomized controlled clinical trial. Twenty four adults ages 18-65 with the primary DSM-IV Schizophrenia and Schizoaffective disorder and drug-refractory persecutory delusions will be recruited from outpatient clinics in New York City Metropolitan area. Participants will be randomly assigned to either experimental or control group. The experimental group will receive PFCBT in addition to standard care and the control group will receive standard care alone. PFCBT will include participation in one group session and one individual therapy session weekly over the 15 weeks. The preliminary efficacy of the intervention will be evaluated using standardized measures by blind evaluators conducted at baseline, post-treatment, and at 6-months post-termination follow-up.
FIELD: medicine. SUBSTANCE: method involves making operation without bandaging and intersecting aortal and inferior vena cava branches, neurovascular fascicles of vertebral bodies, without separating and displacing musculus teres and psoas major, without traumatizing nerve plexuses, dissecting anterior longitudinal ligament without mobilizing and displacing bifurcations of aorta and vena cava of thoracic lymphatic duct. Cortical layer is removed at the level of 1-2 segments of the sacrum and spongy matter is removed from the bodies of 3-5 lumbar vertebrae in operating with instruments in proximal direction. The defect is widened beyond the entrance opening. It is filled with autotransplants undergone to antibiotics and ultraviolet rays treatment and bone fragments. The last transplants are placed in oblique transverse directions, bringing their ends in engagement with the edges of the entrance opening. EFFECT: enhanced effectiveness of surgical treatment.
Dexmedetomidine given as 2mcg/kg bolus over 10 minutes followed by 1.5mcg/kg/hr infusion for duration of scan. The bolus may be repeated up to 2 times at any time during the sedation in the event that adequate sedation conditions (minimum Ramsay Sedation Score of 4) are not achieved. In the event that dexmedetomidine is unable to achieve motionless conditions, after a total of 3 boluses, 0.5 mg/kg IV pentobarbital may be administered at q1 minute intervals up to a maximum of 2 mg/kg, per established protocol.
We report the case of a middle-aged hypertensive woman presenting to the neurology department with short-lasting episodic headaches for 4 years. She was initially diagnosed and treated with cluster headaches for one year. Following this, she presented with right lower limb arterial claudication. Arterial Doppler of lower limbs showed thrombosis of the bilateral common femoral arteries. Further computed tomography (CT) angiogram of the lower limbs confirmed extensive arterial thrombosis in bilateral lower limbs. The CT angiogram incidentally detected a left adrenal lesion. She had elevated urinary vanillylmandelic Acid and 24-hour metanephrines suggesting the presence of a pheochromocytoma. She was initially medically managed and later underwent left open adrenalectomy. Histopathology examination of the sections proved pheochromocytoma. Postsurgery, the patient's symptoms improved remarkably. This case highlights the importance of diagnosing pheochromocytoma when you encounter a patient with refractory short-lasting headaches, hypertension and hypercoagulability.
Patients receive selinexor PO BIW. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity. Blood will be collected for correlative studies to perform pK (pharmacokinetics) and pDn (pharmacodynamics) analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a frustrating outcome and there is no effective targeted immunotherapy against T-ALL. The expansion of chimeric antigen receptor T Cells (CART) to T-ALL remains challenging because co-expression of target antigens between CART and T-ALL primary cells results in CART phase residues. CD1a is expressed in only one of the major sub-classes of T-ALL, cortical T-ALL. Expression of CD1a is restricted to cortical thymocytes, and neither CD34+ progenitors nor T cells express CD1a during ontogeny, thus limiting the risk of targeted/non-tumor toxicity. The present invention provides CARs comprising a CD1a targeting moiety that can be transduced or transformed into a T cell. The CART thus produced is suitable for the treatment of cortical T-ALL.
Approximately 5 mL liquid of tricaprilin using various flavoring agents (swish and expectorate) up to 20 times. Dose will not be ingested.
Heel prick blood collection, which is one of the painful medical procedures, is one of the diagnostic methods used in newborns and is a more painful procedure compared to other blood collection procedures. Prevention of pain in newborns should be the primary goal of all healthcare personnel working with newborns, both because it is an ethical obligation and because repeated painful exposures have the potential to cause harmful consequences. Nonpharmacologic methods used for the control of acute pain associated with medical procedures are easy to use, have no side effects, are inexpensive and time-saving. Mechanical vibration and ShotBlocker application are among the non-pharmacologic methods frequently used in the management of pain associated with heel prick procedure in term infants.

Previous studies have shown that parent-related methods (kangaroo care, mother/father hug, breastfeeding, etc.) are commonly used for pain management of the newborn during heel prick. In this respect, it is important to determine the effectiveness of mechanical vibration and ShotBlocker methods that can be used independently of the parent, especially in intensive care settings where access to the parent is not always possible.
Daily or twice daily injections are a standard part of controlled ovarian stimulation for in-vitro fertilization (IVF). These injections are both physically and emotionally burdensome for patients and contribute additional stressors to those already inherent to infertility. Subcutaneous catheters have been demonstrated to be effective for administration of insulin, anticoagulants, and other medications in pediatric patients, and subcutaneous gonadotropin-releasing hormone pumps have also been used in hypothalamic patients. This study aims to assess the feasibility of a subcutaneous catheter in patients undergoing ovarian stimulation for IVF. Primary outcomes will include the incidence of safety and catheter-related issues as well as assessment of patient satisfaction in cycles using the subcutaneous catheter. We will also closely monitor estradiol and follicle-stimulating hormone levels during stimulation to ensure adequate medication administration via the catheter as well as IVF outcomes including mature oocyte yield, embryo maturation, and pregnancy rates.
Background: Quantitative neuromuscular monitoring is the gold standard to detect postoperative residual curarization (PORC). Many anesthesiologists, however, use insensitive, qualitative neuromuscular monitoring or unreliable, clinical tests. Goal of this multicentre, prospective, double-blinded, assessor controlled study is to develop an algorithm of muscle function tests to identify PORC.

Methods: After extubation a blinded anesthetist performs eight clinical tests in 165 patients. Test results are correlated to calibrated electromyography train-of-four (TOF) ratio and to a postoperatively applied uncalibrated acceleromyography. A classification and regression tree (CART) is calculated developing the algorithm to identify PORC. This is validated against uncalibrated acceleromyography and tactile judgement of TOF fading in separate 100 patients.
Cobicistat is an inhibitor of CYP3A and CYP2D6. The transporters that cobicistat inhibits include p-glycoprotein (P-gp), BCRP, OATP1B1, and OATP1B3. The plasma concentration of drugs that are primarily metabolized by CYP3A or CYP2D6, or are substrates of P-gp, BCRP, OATP1B1, or OATP1B3 may be increased if those drugs are coadministered with TYBOST.

Based on in vitro data, cobicistat is not expected to induce CYP1A2 or CYP2B6 and based on in vivo data, cobicistat is not expected to induce MDR1 or, in general, CYP3A to a clinically significant extent. The induction effect of cobicistat on CYP2C9, CYP2C19, or UGT1A1 is unknown, but is expected to be low based on CYP3A in vitro induction data.

Coadministration of TYBOST with atazanavir or darunavir with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events is contraindicated. Coadministration with drugs that have active metabolite(s) formed by CYP3A may result in reduced plasma concentrations of these active metabolite(s). Coadministration with other CYP3A substrates may require a dose adjustment or additional monitoring as shown in Table 6.
Methods and systems that provide annotation, measurement, phenotyping, diagnosis (AMPD), and other medical predictions from a medical image are disclosed. In these systems, a medical image may be presented in an interface, such as a graphical user interface. When a trained person clicks on a point or indicates a region, a machine learning segmentation model segments the area around the point or region to identify one or more lesions. Machine models are used to establish the measurements, phenotypical characteristics, and diagnosis or other medical predictions. Those machine models may be trained to use the measurements, the phenotypical characteristics, or image features descriptive of the lesion in making the medical predictions. The image features descriptive of the lesion may be deep features extracted from a deep learning segmentation model, or they may be radiomic features.
BACKGROUND: Many randomized controlled trials (RCTs) have reported the complications of corticosteroids for patients with community-acquired pneumonia with inconsistent results. An explicit systematic review and meta-analysis were conducted in this study to evaluate the complications of corticosteroids for patients with community-acquired pneumonia.
METHODS: Using PubMed, Embase, the Global Index Medicus of the World Health Organization (WHO), the WHO clinical trial registry, and Clinicaltrials.gov, a thorough literature search of RCTs was carried out. Inclusion criteria included RCTs comparing the use of any kind of a specified corticosteroid with the placebo control group. The complications were analyzed, including gastrointestinal (GI) bleeding, healthcare-associated infection (HAI), acute kidney injury (AKI), hospital readmission, hyperglycemia, neuropsychiatric complications, and adverse cardiac events.
RESULTS: The result can be concluded that the risk of gastrointestinal (GI) bleeding, healthcare-associated infection (HAI), acute kidney injury (AKI), hospital readmission, neuropsychiatric complications, and adverse cardiac events between the intervention and control groups were not significantly different. However, corticosteroids can increase the risk of hyperglycemia as compared to the control group who did not receive corticosteroids (RR= 1.72, 95 % CI: 1.38-2.14, P < .01). In the subgroup analysis, the meta-analysis showed a significant difference in the risk of hyperglycemia between the prednisolone and control groups (RR= 1.81, 95 % CI: 1.29-2.54, P < .01). There is no heterogeneity between studies (I2= 0%). The subgroup difference was not significant (P = .11).
CONCLUSIONS: Through our analysis, the use of corticosteroids can increase the risk of hyperglycemia for patients with community-acquired pneumonia. Further studies are required to be conducted to confirm the findings due to limited clinical trials.
The invention relates to a computer-implemented method for associating a medical image data set with a medical comparison image data set on the basis of biometric data. The method comprises the method steps of receiving (REC-1) a medical image data set. The method further comprises a method step of receiving (REC-2) at least one medical comparison image data set. The method further comprises a method step of extracting (EXT-1) biometric data based on the medical image dataset. The method further comprises a method step of extracting (EXT-2) biometric comparison data based on the medical comparison image dataset. The method further comprises a method step of determining (DET-1) an amount of deviation between the biometric comparison data and the biometric data. The method further comprises the following method steps: associating (CON) the medical image data set with the medical comparison image data set when the amount of deviation is below a threshold.
The invention discloses a preparation method and application for lignan glycoside. The novel lignan glycoside has a structural formula as shown in the specification, a molecular formula of C27H34O13 and a molecular weight of 566. The lignan glycoside is named as Perovskia lignan glycoside A (1). According to the preparation method provided by the invention, a whole dried Perovskia plant is used as a raw material; and the steps of crushing and extraction, organic-solvent extraction, silica-gel column chromatography and high-pressure liquid-phase chromatographic separation are carried out. According to the application provided by the invention, the Perovskia lignan glycoside A is applied in preparation of drugs for hepatitis B virus (HBV). In-vitro anti-HBV activity experiments show that the Perovskia lignan glycoside A can significantly inhibit HBsAg and HBeAg secreted by HepG2.2.15 cells and reduce HBV DNA in the cells. The Perovskia lignan glycoside A provided by the invention is lignan monoglucoside with a novel structure, has good activity, can be used as a leading compound of anti-HBV drugs, and has good application prospects.
For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container.
The liver is the chief site of biotransformation of phenytoin; patients with impaired liver function, elderly patients, or those who are gravely ill may show early signs of toxicity.

A small percentage of individuals who have been treated with phenytoin have been shown to metabolize the drug slowly. Slow metabolism may be due to limited enzyme availability and lack of induction; it appears to be genetically determined.

Phenytoin should be discontinued if a skin rash appears (see WARNINGS section regarding drug discontinuation). If the rash is exfoliative, purpuric, or bullous or if lupus erythematosus, Stevens-Johnson syndrome, or toxic epidermal necrolysis is suspected, use of this drug should not be resumed and alternative therapy should be considered. (See ADVERSE REACTIONS section.) If the rash is of a milder type (measles-like or scarlatiniform), therapy may be resumed after the rash has completely disappeared. If the rash recurs upon reinstitution of therapy, further phenytoin medication is contraindicated.

Phenytoin and other hydantoins are contraindicated in patients who have experienced phenytoin hypersensitivity (see CONTRAINDICATIONS). Additionally, caution should be exercised if using structurally similar compounds (e.g., barbiturates, succinimides, oxazolidinediones, and other related compounds) in these same patients.

Hyperglycemia, resulting from the drug's inhibitory effects on insulin release, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients.

Osteomalacia has been associated with phenytoin therapy and is considered to be due to phenytoin's interference with vitamin D metabolism. Phenytoin is not indicated for seizures due to hypoglycemic or other metabolic causes. Appropriate diagnostic procedures should be performed as indicated.

Phenytoin is not effective for absence (petit mal) seizures. If tonic-clonic (grand mal) and absence (petit mal) seizures are present, combined drug therapy is needed.

Serum levels of phenytoin sustained above the optimal range may produce confusional states referred to as "delirium," "psychosis," or "encephalopathy," or rarely irreversible cerebellar dysfunction. Accordingly, at the first sign of acute toxicity, plasma levels are recommended. Dose reduction of phenytoin therapy is indicated if plasma levels are excessive; if symptoms persist, termination is recommended. (See WARNINGS section.)
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention proposes new derivatives of phenylaminoimidazoline or phenyliminoimidazolidine of the general formula (Ib) α 1L  or (II)  , respectively. Radical values are given in the invention claim. Indicated isomers by a double bond elicit the property of agonist of  -adrenoceptors. Also, invention proposes a pharmaceutical composition based on thereof. EFFECT: expanded assortment of agents of indicated designation, valuable medicinal properties of compounds. 7 cl, 1 tbl, 4 ex
Once the MTD(s) has been determined, up to 9 subjects of the total enrolled in Part 2 will be entered in the Pharmacokinetic/Pharmacodynamic Cohort. Subjects will be enrolled in this cohort to explore whether exposure to GSK2110183 at dose identified in Part 1 is similar when GSK2110183 is administered alone or in combination with bortezomib and dexamethasone. The same relationship will be explored for bortezomib and dexamethasone when the two drugs are give alone or in combination with GSK2110183.
PURPOSE: An antiviral composition against VHSV(Viral Hemorrhagic Septisemia Virus) containing curcumin as an active ingredient is provided to improve a cell survival rate by 5 times. CONSTITUTION: An antiviral composition against VHSV contains curcumin as an active ingredient. The virus is infectious virus in fish including Paralichthys olivaceus, tripletail, Takifugu rubripes, Goldstriped amberjack, trout, great amberjack, horse mackerel, sea bass, tuna blue-fin, carp, zebra fish, catfish, tilapia, salmon, and Oryzias latipes. The composition suppresses expression of PGC-1alpha(peroxisome proliferator-activated receptor gamma coactivator 1alpha). A Curcuma longa L., tumeric extract contains curcumin. A composition for a fish feed for preventing or treating diseases caused by VHSV contains curcumin as an active ingredient.